Polymerase Chain Reaction (PCR) in Hamatological malignancies
Polymerase chain reaction (PCR) is a technique used in molecular biology to amplify a single or a few copies of a segment of DNA across several orders of magnitude, generating many copies of a particular DNA sequence. PCR has rapidly become an invaluable technique for the detection and clinical management of a wide variety of haematological disorders. It provides a rapid method for the generation of large quantities of relatively pure DNA sequences of interest. This facilitates nucleotide sequence analysis in both normal and pathological haemopoietic populations. It also aids in the characterisation of normal molecular organisation and of inherited and acquired genetic defects. The extreme sensitivity of detection of rare genetic events has greatly improved the ability to detect minimal residual malignancy and low levels of viral infection. PCR is more advanced in that genetically modifies abnormal cells can be detected within a normal cell population at far low incidence level than any other existing technology. Advancements in PCR help in Detection of Mutated Genes, Detection of Chromosomal Translocations, Detection of Gene Expression, Detection of Clonality and sequencing.
- Principles
- Research
- Applications
- Advantages
- Limitations
Related Conference of Polymerase Chain Reaction (PCR) in Hamatological malignancies
Polymerase Chain Reaction (PCR) in Hamatological malignancies Conference Speakers
Recommended Sessions
- Hemato-Oncology
- Biomarkers in Hematology
- Blood Disorders
- Blood Disorders Diagnosis and Treatment
- Blood transfusion
- Hematology
- Hematology Nursing
- Hematopathology
- Immunohematology
- Pediatric Hematology
- Polymerase Chain Reaction (PCR) in Hamatological malignancies
- Stem cell research
- Thalassemia
- Veterinary Hematology
Related Journals
Are you interested in
- Bleeding Disorders in Women - Blood Disorders 2024 (Ireland)
- Digital Health and Artificial Intelligence (AI) in Hematology - Blood Disorders 2024 (Ireland)
- Hematologic Gene Editing and Gene Therapies - Blood Disorders 2024 (Ireland)
- Hematology and Stem Cell Research - Blood Disorders 2024 (Ireland)
- Hematopoietic Stem Cell Transplantation - Blood Disorders 2024 (Ireland)
- Hemoglobinopathies and Sickle Cell Disease - Blood Disorders 2024 (Ireland)
- Hemophilia Management and Research - Blood Disorders 2024 (Ireland)
- Hemostasis and Thrombosis - Blood Disorders 2024 (Ireland)
- Immunotherapy and Hematology - Blood Disorders 2024 (Ireland)
- Leukemia and Lymphoma - Blood Disorders 2024 (Ireland)
- Medicine in Hematology - Blood Disorders 2024 (Ireland)
- Molecular Hematology - Blood Disorders 2024 (Ireland)
- Myelodysplastic Syndromes (MDS) and Bone Marrow Failure - Blood Disorders 2024 (Ireland)
- Next-Generation Diagnostics and Imaging - Blood Disorders 2024 (Ireland)
- Novel Therapies for Blood Cancers - Blood Disorders 2024 (Ireland)
- Pediatric Hematology - Blood Disorders 2024 (Ireland)
- Platelet Disorders - Blood Disorders 2024 (Ireland)
- Sickle Cell Disease (SCD) - Blood Disorders 2024 (Ireland)
- Thalassemia Management - Blood Disorders 2024 (Ireland)
- Transfusion Medicine and Blood Banking - Blood Disorders 2024 (Ireland)